Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors

BACKGROUND: Aromatase inhibitors (AIs) have not been used consistently as part of the management of hormone receptor positive uterine leiomyosarcomas (ULMS). As a result, the published data regarding the efficacy of AIs in this subtype of ULMS are sparse. METHODS: We performed a retrospective electr...

Descripción completa

Detalles Bibliográficos
Autores principales: Thanopoulou, Eirini, Thway, Khin, Khabra, Komel, Judson, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094538/
https://www.ncbi.nlm.nih.gov/pubmed/25018868
http://dx.doi.org/10.1186/2045-3329-4-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094538/
https://www.ncbi.nlm.nih.gov/pubmed/25018868
http://dx.doi.org/10.1186/2045-3329-4-5

Ejemplares similares